$PRPH
ProPhase Labs, Inc. Stock $prph

$prph Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000086827824000004 Filed on March 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$3.634M	$4.351M	$45.24M
YoY Change	-81.17%	-80.06%	-63.12%
Cost Of Revenue	$4.067M	$7.407M	$29.00M
YoY Change	-53.69%	-29.72%	-44.23%
Gross Profit	-$433.0K	-$3.056M	$16.24M
YoY Change	-104.12%	-127.08%	-77.02%
Gross Profit Margin	-11.92%	-70.24%	35.9%
Selling, General & Admin	$7.593M	$8.022M	$34.50M
YoY Change	-8.5%	-37.04%	0.34%
% of Gross Profit			212.46%
Research & Development	$272.0K	$274.0K	$1.418M
YoY Change	88.89%	-42.68%	102.57%
% of Gross Profit			8.73%
Depreciation & Amortization	$1.686M	$1.842M	$6.277M
YoY Change	30.5%	98.92%	33.04%
% of Gross Profit			38.65%
Operating Expenses	$7.865M	$8.296M	$37.85M
YoY Change	-18.46%	-49.33%	-19.56%
Operating Profit	-$8.298M	-$11.35M	-$21.61M
YoY Change	-1048.34%	123.03%	-191.6%
Interest Expense	$515.0K	-$455.0K	-$1.197M
YoY Change	139.53%	359.6%	-256.68%
% of Operating Profit
Other Income/Expense, Net	-$18.00K	$142.0K	$10.00K
YoY Change	-83.18%
Pretax Income	-$8.831M	-$11.67M	-$22.80M
YoY Change	-1665.78%	124.8%	-199.53%
Income Tax	-$2.566M	-$2.914M	-$6.018M
% Of Pretax Income
Net Earnings	-$6.265M	-$8.751M	-$16.78M
YoY Change	-1239.09%	258.06%	-190.9%
Net Earnings / Revenue	-172.4%	-201.13%	-37.1%
Basic Earnings Per Share	-$0.35		-$0.98
Diluted Earnings Per Share	-$0.35	-$0.48	-$0.98
COMMON SHARES
Basic Shares Outstanding	18.05M shares	18.05M shares	17.21M shares
Diluted Shares Outstanding	18.05M shares		17.21M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.233M	$4.736M	$4.736M
YoY Change	-92.08%	-72.84%	-72.84%
Cash & Equivalents	$1.175M	$1.609M	$1.609M
Short-Term Investments	$58.00K	$3.127M	$3.127M
Other Short-Term Assets	$4.938M	$2.695M	$2.695M
YoY Change	38.2%	13.91%	13.91%
Inventory	$3.758M	$3.841M	$3.841M
Prepaid Expenses
Receivables	$35.12M	$36.31M	$36.31M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$45.05M	$47.59M	$47.59M
YoY Change	-26.49%	-21.78%	-21.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.26M	$17.47M	$17.47M
YoY Change	94.12%	139.71%	53.96%
Goodwill	$5.231M	$5.231M
YoY Change	0.0%	-8.37%
Intangibles	$11.69M	$12.33M
YoY Change	-19.53%	45.52%
Long-Term Investments
YoY Change
Other Assets	$316.0K	$9.308M	$9.308M
YoY Change	-72.83%	700.34%	624.92%
Total Long-Term Assets	$44.99M	$44.34M	$44.34M
YoY Change	31.95%	65.36%	65.36%
TOTAL ASSETS
Total Short-Term Assets	$45.05M	$47.59M	$47.59M
Total Long-Term Assets	$44.99M	$44.34M	$44.34M
Total Assets	$90.03M	$91.93M	$91.93M
YoY Change	-5.6%	4.88%	4.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.76M	$9.383M	$9.383M
YoY Change	141.66%	58.9%	58.9%
Accrued Expenses	$1.235M	$1.291M	$1.291M
YoY Change	53.99%	80.81%	-62.91%
Deferred Revenue	$1.630M	$2.382M
YoY Change
Short-Term Debt	$2.381M	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.840M	$1.840M	$1.840M
YoY Change
Total Short-Term Liabilities	$23.91M	$20.86M	$20.86M
YoY Change	29.46%	29.75%	29.75%
LONG-TERM LIABILITIES
Long-Term Debt	$6.668M	$7.016M	$7.016M
YoY Change	177.83%	192.33%	192.33%
Other Long-Term Liabilities	$14.59M	$14.67M	$14.67M
YoY Change	0.16%	175.87%	175.87%
Total Long-Term Liabilities	$21.26M	$21.69M	$21.69M
YoY Change	25.3%	173.07%	180.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.91M	$20.86M	$20.86M
Total Long-Term Liabilities	$21.26M	$21.69M	$21.69M
Total Liabilities	$45.17M	$42.54M	$42.54M
YoY Change	27.47%	77.14%	77.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$11.29M	-$5.029M
YoY Change	-191.8%	-142.79%
Common Stock	$18.00K	$18.00K
YoY Change	5.88%	12.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$44.87M	$49.38M	$49.38M
YoY Change
Total Liabilities & Shareholders Equity	$90.03M	$91.93M	$91.93M
YoY Change	-5.6%	4.88%	4.88%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$6.265M	-$8.751M	-$16.78M
YoY Change	-1239.09%	258.06%	-190.9%
Depreciation, Depletion And Amortization	$1.686M	$1.842M	$6.277M
YoY Change	30.5%	98.92%	33.04%
Cash From Operating Activities	-$5.119M	-$213.0K	-$11.35M
YoY Change	-1175.42%	-126.26%	-139.68%
INVESTING ACTIVITIES
Capital Expenditures	$939.0K	$1.310M	$3.155M
YoY Change	-72.55%	-17.92%	-19.49%
Acquisitions	$0.00		$2.904M
YoY Change	-100.0%
Other Investing Activities	$3.374M	$46.00K	$1.786M
YoY Change	90.73%	-101.35%	-3.04%
Cash From Investing Activities	$2.435M	-$1.264M	-$1.369M
YoY Change	-247.4%	-74.74%	-34.09%
FINANCING ACTIVITIES
Cash Dividend Paid			$0.00
YoY Change			-100.0%
Common Stock Issuance & Retirement, Net			-$4.767M
YoY Change			-321.51%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.271M	2.924M	5.757M
YoY Change	35.18%	-130.79%	-122.12%
NET CHANGE
Cash From Operating Activities	-$5.119M	-213.0K	-11.35M
Cash From Investing Activities	$2.435M	-1.264M	-1.369M
Cash From Financing Activities	$2.271M	2.924M	5.757M
Net Change In Cash	-$413.0K	1.447M	-6.960M
YoY Change	-181.94%	-110.57%	-1643.24%
FREE CASH FLOW
Cash From Operating Activities	-$5.119M	-$213.0K	-$11.35M
Capital Expenditures	$939.0K	$1.310M	$3.155M
Free Cash Flow	-$6.058M	-$1.523M	-$14.50M
YoY Change	105.7%	94.01%	-158.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-21617
CY2023	dei	Entity Registrant Name EntityRegistrantName	ProPhase Labs, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	23-2577138
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	711 Stewart Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Garden City
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11530
CY2023	dei	City Area Code CityAreaCode	(215)
CY2023	dei	Local Phone Number LocalPhoneNumber	345-0919
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0005 par value per share
CY2023	dei	Trading Symbol TradingSymbol	PRPH
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Auditor Firm AuditorFirmId	536
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1609000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	540000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3127000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3976000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	60833000	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	121000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4059000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8475000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	5709000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1163000	usd
CY2023Q4	us-gaap	Assets Assets	91927000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9383000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	314000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	24000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	37852000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	47059000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21613000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	23595000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000868278
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	100240301	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18045209	shares
CY2023	dei	Auditor Name AuditorName	Morison Cogen LLP
CY2023	dei	Auditor Location AuditorLocation	Blue Bell, Pennsylvania
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9109000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8328000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36313000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37054000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	3841000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2155000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2366000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	47585000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	12898000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7288000	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	832000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4572000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12333000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	5231000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	7313000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1163000	usd
CY2022Q4	us-gaap	Assets Assets	87648000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5905000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1009000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	99000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1840000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	953000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	301000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2382000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2499000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	3278000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	4190000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2683000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2072000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20857000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16075000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	341000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2924000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2023Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	2000000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1100000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1418000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	652000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1059000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	224000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4092000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4237000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4259000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	21687000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7942000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	42544000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	24017000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18045029	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16210776	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	18000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	16000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	118694000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	109138000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5029000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	11753000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	18940967	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	18126790	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	64000000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	58033000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-300000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	757000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	49383000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	63631000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	91927000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87648000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44384000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	122647000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	51993000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	421000	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	78000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	153000	usd
CY2023	us-gaap	Interest Expense InterestExpense	1275000	usd
CY2022	us-gaap	Interest Expense InterestExpense	764000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-76000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22800000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	22908000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6018000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4445000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16782000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18463000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1057000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	932000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17839000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	19395000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.98
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.17
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.98
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.02
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17207000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15845000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17207000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18651000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	58628000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	600000	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2152000	usd
CY2022	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	9352000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7474000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	932000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3986000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18463000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	63631000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1000000	usd
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	588000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2400000	usd
CY2023	prph	Issuance Of Common Stock Upon Exercise Of Warrant Amount IssuanceOfCommonStockUponExerciseOfWarrantAmount	1200000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	398000	usd
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	5379000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1057000	usd
CY2023	prph	Prepaid Share Based Compensation Expense PrepaidShareBasedCompensationExpense	1024000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4560000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16782000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	49383000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16782000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18463000	usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	22000	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-354000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6277000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4718000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	132000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	343000	usd
CY2023	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	23000	usd
CY2022	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	127000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3536000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3986000	usd
CY2023	prph	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	0	usd
CY2022	prph	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	174000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	718000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-761000	usd
CY2023	prph	Inventory Valuation Reserve InventoryValuationReserve	0	usd
CY2022	prph	Inventory Valuation Reserve InventoryValuationReserve	-78000	usd
CY2023	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	91000	usd
CY2022	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	6163000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	68000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4498000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-135000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-702000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	376000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	617000	usd
CY2023	prph	Increase Decrease In Deferred Income Tax Assets IncreaseDecreaseInDeferredIncomeTaxAssets	7313000	usd
CY2022	prph	Increase Decrease In Deferred Income Tax Assets IncreaseDecreaseInDeferredIncomeTaxAssets	0	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	555000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3478000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1121000	usd
CY2023	prph	Increase Decrease In Accrued Diagnostic Services IncreaseDecreaseInAccruedDiagnosticServices	-695000	usd
CY2022	prph	Increase Decrease In Accrued Diagnostic Services IncreaseDecreaseInAccruedDiagnosticServices	-881000	usd
CY2023	prph	Increase Decrease In Accrued Advertising And Other Allowances IncreaseDecreaseInAccruedAdvertisingAndOtherAllowances	-75000	usd
CY2022	prph	Increase Decrease In Accrued Advertising And Other Allowances IncreaseDecreaseInAccruedAdvertisingAndOtherAllowances	-5000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-76000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	619000	usd
CY2023	prph	Increase Decrease In Deferred Income Tax Liabilities IncreaseDecreaseInDeferredIncomeTaxLiabilities	-224000	usd
CY2022	prph	Increase Decrease In Deferred Income Tax Liabilities IncreaseDecreaseInDeferredIncomeTaxLiabilities	-138000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-181000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-301000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-912000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	2878000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	611000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-423000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11348000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	28551000	usd
CY2023	us-gaap	Escrow Deposits Related To Property Sales EscrowDepositsRelatedToPropertySales	478000	usd
CY2022	us-gaap	Escrow Deposits Related To Property Sales EscrowDepositsRelatedToPropertySales	0	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2904000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2023	prph	Issuance Of Secured Promissory Note Receivable IssuanceOfSecuredPromissoryNoteReceivable	0	usd
CY2022	prph	Issuance Of Secured Promissory Note Receivable IssuanceOfSecuredPromissoryNoteReceivable	0	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	3819000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	6777000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3817000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1047000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	4168000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	7120000	usd
CY2023	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	46000	usd
CY2022	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	452000	usd
CY2023	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable	0	usd
CY2022	us-gaap	Proceeds From Sale And Collection Of Notes Receivable ProceedsFromSaleAndCollectionOfNotesReceivable	0	usd
CY2023	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3155000	usd
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3919000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1369000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2077000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	10524000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1200000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5379000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7474000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7044000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	588000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2152000	usd
CY2023	us-gaap	Payments Of Dividends PaymentsOfDividends	0	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	9353000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5757000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-26023000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6960000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	451000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9109000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8658000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2149000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9109000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1696000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	932000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	763000	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1024000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	0	usd
CY2023	prph	Issuance Of Common Shares For Debt Conversion IssuanceOfCommonSharesForDebtConversion	2400000	usd
CY2022	prph	Issuance Of Common Shares For Debt Conversion IssuanceOfCommonSharesForDebtConversion	600000	usd
CY2023	prph	Net Unrealized Loss Gain Investments In Marketable Debt Securities NetUnrealizedLossGainInvestmentsInMarketableDebtSecurities	1520000	usd
CY2022	prph	Net Unrealized Loss Gain Investments In Marketable Debt Securities NetUnrealizedLossGainInvestmentsInMarketableDebtSecurities	1294000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	5809000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2023	prph	Issuance Of Warrants With Unsecured Promissory Note IssuanceOfWarrantsWithUnsecuredPromissoryNote	398000	usd
CY2022	prph	Issuance Of Warrants With Unsecured Promissory Note IssuanceOfWarrantsWithUnsecuredPromissoryNote	0	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	1000000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022Q2	prph	Number Of Licensed Compounds NumberOfLicensedCompounds	2	numberoflicensedcompound
CY2022Q2	prph	Number Of Inhibitors NumberOfInhibitors	2	inhibitor
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business and Liquidity Risks and Uncertainties</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our diagnostic service business continued to be impacted by the level of demand for COVID-19 and other diagnostic testing, the prices we are able to receive for performing our testing services, our ability to collect payment or reimbursement for our testing services in December 31, 2023 and ultimately led to our revenues decreasing significantly for the year ended December 31, 2023. On March 22, 2022, the Health Resources & Services Administration ("HRSA") program stopped accepting claims for COVID-19 testing and treatment provided to uninsured individuals due to lack of sufficient funds. We recognized approximately 1,000,000 tests for the year ended December 31, 2022 and approximately 480,000 tests for the year ended December 31, 2023, of which 28% were reimbursed by the HRSA uninsured program for the year ended December 31, 2022, and none were reimbursed from the HRSA uninsured program for the year ended December 31, 2023. As a result, we have reduced the amount of diagnostic testing services that we provide since the second half of 2023. Nonetheless we are prepared to provide an increased volume of our diagnostic testing service if diagnostic testing is required due to a new COVID-19 outbreak. We have continued to ship COVID-19 antigen kits under an existing contract to our customer. In addition, in order to maintain licenses in certain states in which we operate, we currently perform several diagnostic tests each quarter to maintain our certified lab status, and we currently plan to do so for the foreseeable future. There is no guarantee that the demand of our diagnostic testing services will increase or meet the level of demand that we experienced during the COVID-19 pandemic, and there is no guarantee that we will be able to substitute the revenues previously generated from this line of business from our other business lines.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our personal genomics business is and will continue to be influenced by demand for our genetic sequencing products and services, our marketing and service capabilities, and our ability to comply with applicable regulatory requirements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our contracting manufacturing business is and will continue to be impacted by demand for our services, which is largely a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period from September to March when the incidence of the common cold rises as a result of the change in weather and other factors. We generally experience in the first, third and fourth quarter higher levels of net revenues from our contract manufacturing business. Revenues are generally at their lowest levels in the second quarter when customer demand generally declines. This line of business is also impacted by our ability to meet such demands. The building of our manufacturing facilities and manufacturing of products necessitates compliance with applicable regulatory requirements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consumer sales are and will continue to be impacted by (i) the timing of acceptance of our TK Supplements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consumer products in the marketplace, and (ii) fluctuations in the timing of purchase and the ultimate level of demand for these products. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, $11.3 million was used by operating activities. The Company had cash, cash equivalents, restricted cash and marketable securities of $5.3 million as of December 31, 2023. Based on management’s current business plans, the Company estimates that it will have enough cash and liquidity to finance its operating requirements for at least one year from the date of filing these financial statements. However, due to the nature of the diagnostic business and the Company's focus thus far on COVID-19, there are inherent uncertainties associated with managements’ business plan and cash flow projections if the Company is unable to grow its diagnostic testing business beyond COVID-19 testing services and to grow its other businesses.</span></div>As such, the Company’s future capital needs and the adequacy of its available funds will depend on many factors. These include, but not necessarily limited to, the actual cost and time necessary to achieve sustained profitability from diagnostic services, the ability to successfully diversify the diagnostic services revenue streams and the ability to market and grow the personal genomics, biopharma, manufacturing and supplement businesses. The Company may be required to raise additional funds through equity or debt securities offerings or strategic collaboration and/or licensing agreements in order to fund operations until it is able to generate enough revenues. Such financing may not be available on acceptable terms, or at all, and the Company’s failure to raise capital when needed could have a material adverse effect on its strategic objectives, results of operations and financial condition.<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Financial Risks</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments, marketable debt securities, and trade accounts receivable. Our marketable securities are fixed income investments, which are highly liquid and can be readily purchased or sold through established markets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain cash and cash equivalents with certain major financial institutions. As of December 31, 2023, our cash and cash equivalents and restricted cash balance was $2.1 million. Of the total bank balance, $1.0 million was covered by federal depository insurance and $1.1 million was uninsured at December 31, 2023.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable subject us to credit risk concentrations from time-to-time. We extend credit to our consumer healthcare product customers based upon an evaluation of the customer’s financial condition and credit history and generally do not require collateral. Our diagnostic services receivable credit risk is based on payer reimbursement experience, which includes government agencies and healthcare insurers, the period the receivables have been outstanding and the historical collection rates. The collectability of the diagnostic services receivables is also directly linked to the quality of our billing processes, which depend on information provided and billing services of third parties. These credit concentrations impact our overall exposure to credit risk, which could be further affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of trade receivables and diagnostic test receivables. Additionally, the reimbursement receivables from the diagnostic service business are subject to billing errors and related disputes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, see Note 13 - Significant Customers Concentrations.</span></div>
CY2022	prph	Number Of Tests Recognized NumberOfTestsRecognized	1000000	test
CY2023	prph	Number Of Tests Recognized NumberOfTestsRecognized	480000	test
CY2022	prph	Number Of Tests Recognized Reimbursed By Hrsa Uninsured Program Percentage NumberOfTestsRecognizedReimbursedByHRSAUninsuredProgramPercentage	0.28
CY2023	prph	Number Of Tests Recognized Reimbursed By Hrsa Uninsured Program Percentage NumberOfTestsRecognizedReimbursedByHRSAUninsuredProgramPercentage	0
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11300000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	5300000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements and the accompanying notes thereto, in conformity with generally accepted accounting principles in the United States of America (“GAAP”), requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the impact of the variable consideration around diagnostic test reimbursement rates, the provision for uncollectible receivables and billing errors, sales returns and allowances, rates, slow moving, dated inventory and associated provisions, the estimated useful lives and potential impairment of long-lived assets, stock based compensation valuation, income tax asset valuations and assumptions related to accrued advertising.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</span></div>
CY2023Q4	us-gaap	Escrow Deposit EscrowDeposit	540000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	3528000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	401000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3127000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	7186000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1234000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	92000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8328000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	40177000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	37568000	usd
CY2023Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	0	usd
CY2022Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2626000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	40177000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	40194000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3864000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3140000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	36313000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	37054000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3140000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	724000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3864000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3900000	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	5500000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3100000	usd
CY2023Q4	prph	Inventory Lab Material InventoryLabMaterial	623000	usd
CY2022Q4	prph	Inventory Lab Material InventoryLabMaterial	1739000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1619000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1639000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	306000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	754000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1551000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	356000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	4099000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	4488000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	258000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	512000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	3841000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3976000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2100000	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	1000000	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1100000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	3127000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	8328000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3500000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3600000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2382000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2499000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	750000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	683000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	350000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	376000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3482000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	3558000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44384000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	122647000	usd
CY2023Q1	prph	Asset Acquisition Consideration Transferred Promissory Note Payoff AssetAcquisitionConsiderationTransferredPromissoryNotePayoff	400000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2023Q1	prph	Asset Acquisition Shares Issued And Issuable Value Per Share AssetAcquisitionSharesIssuedAndIssuableValuePerShare	10.00
CY2023Q1	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	4600000	usd
CY2023Q1	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	500000	usd
CY2023Q1	prph	Asset Acquisition Consideration Transferred Promissory Note Payoff AssetAcquisitionConsiderationTransferredPromissoryNotePayoff	400000	usd
CY2023Q1	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	2000000	usd
CY2023Q1	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	2000000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1400000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	700000	usd
CY2023Q1	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	500000	usd
CY2023Q1	prph	Asset Acquisition Consideration Transferred Liability Payoff AssetAcquisitionConsiderationTransferredLiabilityPayoff	1600000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	24432000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	15728000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y
CY2023Q1	prph	Asset Acquisition Transaction Costs AssetAcquisitionTransactionCosts	200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19101000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12297000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6768000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3822000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12333000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8475000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2900000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2583000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2583000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2251000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1731000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	370000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2815000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12333000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	11534000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	8440000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	12898000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7288000	usd
CY2023	us-gaap	Depreciation Depreciation	3100000	usd
CY2022	us-gaap	Depreciation Depreciation	2300000	usd
CY2022Q1	us-gaap	Cash Cash	1400000	usd
CY2022Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	1400000	usd
CY2022Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	41000	usd
CY2022Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	5.75
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1200000	usd
CY2022Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	2600000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2022Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.30
CY2022Q2	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	4700000	usd
CY2022Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.30
CY2022Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	4600000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	6000000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P9M
CY2023Q1	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P9M
CY2022Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	6000000	usd
CY2022Q3	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P6M
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	69628	shares
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	303145	shares
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	600000	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2200000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5110000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.27
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y4M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	20820000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1095000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.92
CY2022	prph	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P7Y
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1833000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.29
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	420000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.56
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3952000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.35
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	20379000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1135000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.65
CY2023	prph	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P5Y
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1348000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.98
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	788000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.64
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2951000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.30
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	693000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1880000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.69
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	693000	usd
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	4.52
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.63
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5400000	usd
CY2023	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	603881	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1833000	shares
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7500000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1135000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1095000	shares
CY2023	prph	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	4200000	usd
CY2022	prph	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	6100000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	8.65
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	10.03
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y8M12D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y6M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.80
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.79
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.037
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.025
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	10.00
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P5Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	300000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P1Y
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5100000	usd
CY2023Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1200000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.00
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	0	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1133000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3500000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5100000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y3M18D
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	772000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1040000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	284000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3543000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1056000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4583000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5459000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	72000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1615000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-210000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-7074000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-138000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6018000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4445000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4788000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	4811000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2789000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	350000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1200000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	510000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-601000	usd
CY2023	prph	Income Taxes From Continuing Operations Before Valuation Allowance IncomeTaxesFromContinuingOperationsBeforeValuationAllowance	-5761000	usd
CY2022	prph	Income Taxes From Continuing Operations Before Valuation Allowance IncomeTaxesFromContinuingOperationsBeforeValuationAllowance	5799000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-257000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1354000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6018000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4445000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6018000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4445000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4649000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1324000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1464000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1466000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4972000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2684000	usd
CY2023Q4	prph	Deferred Tax Assets Capital Lease Obligations DeferredTaxAssetsCapitalLeaseObligations	1464000	usd
CY2022Q4	prph	Deferred Tax Assets Capital Lease Obligations DeferredTaxAssetsCapitalLeaseObligations	1466000	usd
CY2023Q4	prph	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	479000	usd
CY2022Q4	prph	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	705000	usd
CY2023Q4	prph	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	1612000	usd
CY2022Q4	prph	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	2703000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	350000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	567000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	824000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	7313000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	224000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1500000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	3100000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	300000	usd
CY2023Q4	prph	Tax Credit Carryforward Limitation Amount TaxCreditCarryforwardLimitationAmount	300000	usd
CY2023Q4	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	0	usd
CY2022Q4	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	1093000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	181000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	202000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1000000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	0	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1445000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	714000	usd
CY2023Q4	prph	Accrued Returns AccruedReturns	3000	usd
CY2022Q4	prph	Accrued Returns AccruedReturns	13000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	54000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	50000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2683000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2072000	usd
CY2021Q2	prph	Manufacturing Agreement Renewal Options ManufacturingAgreementRenewalOptions	4	period
CY2021Q2	prph	Manufacturing Agreement Renewal Period ManufacturingAgreementRenewalPeriod	P1Y
CY2021Q2	prph	Agreement Term AgreementTerm	P90D
CY2022Q4	prph	Manufacturing Agreement Renewal Period ManufacturingAgreementRenewalPeriod	P1Y
CY2023Q1	prph	Number Of Sites NumberOfSites	8	site
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5200000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4600000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4600000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4100000	usd
CY2023Q2	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P5Y
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1500000	usd
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.080
CY2023Q3	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P4Y
CY2023Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	5100000	usd
CY2023Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.074
CY2023Q3	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P3Y
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	760000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	956000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	816000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	956000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	816000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	259000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	760000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	usd
CY2023	prph	Finance Lease Cost FinanceLeaseCost	1019000	usd
CY2022	prph	Finance Lease Cost FinanceLeaseCost	0	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	839000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	774000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y6M
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1000
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1000
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0756
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	5809000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	760000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	952000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1840000	usd
CY2023Q4	prph	Lease Liability To Be Paid Year One LeaseLiabilityToBePaidYearOne	2792000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	977000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	1840000	usd
CY2023Q4	prph	Lease Liability To Be Paid Year Two LeaseLiabilityToBePaidYearTwo	2817000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	941000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	1840000	usd
CY2023Q4	prph	Lease Liability To Be Paid Year Three LeaseLiabilityToBePaidYearThree	2781000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	955000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	1188000	usd
CY2023Q4	prph	Lease Liability To Be Paid Year Four LeaseLiabilityToBePaidYearFour	2143000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	982000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	122000	usd
CY2023Q4	prph	Lease Liability To Be Paid Year Five LeaseLiabilityToBePaidYearFive	1104000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2667000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	prph	Lease Liability To Be Paid After Year Five LeaseLiabilityToBePaidAfterYearFive	2667000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7474000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	6830000	usd
CY2023Q4	prph	Lease Liability To Be Paid LeaseLiabilityToBePaid	14304000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2284000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	898000	usd
CY2023Q4	prph	Lease Liability Undiscounted Excess Amount LeaseLiabilityUndiscountedExcessAmount	3182000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5190000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	5932000	usd
CY2023Q4	prph	Lease Liability LeaseLiability	11122000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44400000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	122600000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44384000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	122647000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28145000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	51993000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6049000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4542000	usd
CY2023	prph	Operating And Other Expenses OperatingAndOtherExpenses	32990000	usd
CY2022	prph	Operating And Other Expenses OperatingAndOtherExpenses	43203000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22800000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	22908000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6018000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4445000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-16782000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	18463000	usd
CY2023Q4	us-gaap	Assets Assets	91927000	usd
CY2022Q4	us-gaap	Assets Assets	87648000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16782000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	18463000	usd
CY2023	prph	Interest On Unsecured Convertible Promissory Note InterestOnUnsecuredConvertiblePromissoryNote	0	usd
CY2022	prph	Interest On Unsecured Convertible Promissory Note InterestOnUnsecuredConvertiblePromissoryNote	632000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16782000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	19095000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17207000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15845000	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	240000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17207000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18651000	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3782000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1225000	shares

Files In Submission

Name	View Source	Status
0000868278-24-000004-index-headers.html	Edgar Link	pending
0000868278-24-000004-index.html	Edgar Link	pending
0000868278-24-000004.txt	Edgar Link	pending
0000868278-24-000004-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image.jpg	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_3.jpg	Edgar Link	pending
literacompareredline-pro.htm	Edgar Link	pending
literacompareredline-pro001.jpg	Edgar Link	pending
literacompareredline-pro002.jpg	Edgar Link	pending
literacompareredline-pro003.jpg	Edgar Link	pending
literacompareredline-pro004.jpg	Edgar Link	pending
literacompareredline-pro005.jpg	Edgar Link	pending
literacompareredline-pro006.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prophase-bylaws2024.htm	Edgar Link	pending
prophase-director2022plano.htm	Edgar Link	pending
prophase-exhibit191.htm	Edgar Link	pending
prophase-exhibit211.htm	Edgar Link	pending
prophase-exhibit3111.htm	Edgar Link	pending
prophase-exhibit3121.htm	Edgar Link	pending
prophase-exhibit3211.htm	Edgar Link	pending
prophase-exhibit3221.htm	Edgar Link	pending
prophase-exhibit971.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
prophase-formof2022planinc.htm	Edgar Link	pending
prophase-formof2022plannqo.htm	Edgar Link	pending
prph-20231231.htm	Edgar Link	pending
prph-20231231.xsd	Edgar Link	pending
prph-exhibit231consent.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
prph-20231231_def.xml	Edgar Link	unprocessable
prph-20231231_lab.xml	Edgar Link	unprocessable
prph-20231231_pre.xml	Edgar Link	unprocessable
prph-20231231_htm.xml	Edgar Link	completed
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
prph-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRPH
ProPhase Labs, Inc. Stock $prph

2024 Q1 Form 10-K Financial Statement

#000086827824000004 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRPH ProPhase Labs, Inc. Stock $prph

2024 Q1 Form 10-K Financial Statement

#000086827824000004 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRPH
ProPhase Labs, Inc. Stock $prph